Best of 18th IASLC World Conference on Lung Cancer (WCLC) 2017

February 23-24 | 2018
Radisson Blu Park Hotel
Athens | Greece

scientific program
FEBRUARY 23rd 2018

11.30-12.15 Registration

12:15-12.50 CLINICAL TRIALS
Chairs: Β. Γεωργούλιας, Δ. Τραφαλής
Presenter: Η. Κοττέας (15 min)

- MA 18.09 ENROLLMENT OF MINORITIES, THE ELDERLY, AND WOMEN IN LUNG CANCER CLINICAL TRIALS
- MA 18.12 QUALITY OF DATA INFORMING EPIDEMIOLOGICAL STUDIES IN PATIENTS WITH LUNG CANCER
- OA 14.02 RETHINKING PROGRESSION-FREE SURVIVAL (PFS) AS A CLINICAL TRIALS SURROGATE FOR OVERALL SURVIVAL (OS)
- OA 14.05 PHASE 2 BASKET TRIAL OF ADO-TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 MUTANT OR AMPLIFIED LUNG CANCERS

Discussant: A. Χαρπίδου (10 min)
Q & A

12:50-13.50 EPIDEMIOLOGY AND PREVENTION OF LUNG CANCER
Chairs: Ε. Ζαχαριάδης, Α. Τσαρουχά
Presenter 1: M. Ζωντανός (20 min)

- PL 01.01 CURRENT STATUS OF SMOKING CESSATION PROGRAM (TOBACCO CONTROL)
- OA 06.01 COSTS AND COST-EFFECTIVENESS OF SMOKING CESSATION WITHIN AN ORGANIZED CT LUNG CANCER (LC) SCREENING PROGRAM
- OA 06.05 SOCIOECONOMIC FACTORS AFFECTING OUTCOMES IN NON-SMALL CELL LUNG CANCER (NSCLC): A LARGE POPULATION BASED ANALYSIS

Presenter 2: N. Μποσταντζόγλου (15 min)

- OA 06.02 FINAL REPORT OF THE INHERIT EGFR STUDY - 33 UNRELATED KINDREDS CARRYING GERMLINE EGFR MUTATIONS
- OA 06.07 SURVIVAL TRENDS AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS OVER A DECADE: IMPACT OF INITIAL THERAPY AT ACADEMIC CENTERS
- MA 18.06 CLINICAL PROGNOSTIC MODEL FOR OLDER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

Discussion: Γ. Κρομμύδας (15 min)
Q & A

13.50-14.35 EDUCATIONAL SESSION
NEW NSCLC STAGING
Chairs: Α. Ράπτη, Λ. Θάνος
Presenter: I. Βαμβακάρης (25 min)

- PL 02.06 THE IASLC LUNG CANCER STAGING PROJECT: ANALYSIS OF RESECTION MARGIN STATUS AND PROPOSALS FOR R STATUS DESCRIPTORS FOR NON-SMALL CELL LUNG CANCER
• ES 01.01 NEW TNM CLASSIFICATION

Discussion: Ι. Γκιόζος (15 min)
Q & A

14:35- 15:00 Coffee break

15:00- 15:45 EARLY STAGE AND LOCALLY ADVANCED NSCLC
Chairs: Κ. Ηλιάδης, Η. Καϊνης

Part I
Presenter: Κ. Βάχλας (10 min)
• OA 04.02 FEASIBILITY OF PULMONARY RESECTION FOLLOWING DEFINITIVE CHEMORADIOThERAPY FOR PRIMARY LUNG CARCINOMA
• OA 04.03 PRIMARY TUMOR RESECTION VERSUS MAINTENANCE THERAPY FOR PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER
• MA 17.08 THE VALIDITY OF TNM CLASSIFICATION AFTER INDUCTION TREATMENT IN PATIENTS WITH NSCLC: PULMONARY RESECTION WITH OR WITHOUT INDUCTION TREATMENT

Discussion: Χ. Πανόπουλος (5 min)
Q & A

Part II
Presenter: Λ. Τουφεξιάν (15 min)
• OA 16.02 RISK OF RECURRENCE IN STAGE I ADENOCARCINOMA OF THE LUNG: A MULTI-INSTITUTIONAL STUDY ON INTERACTION WITH TYPE OF SURGERY AND TYPE OF NODAL STAGING
• OA 16.03 RECURRENCES AND 2ND PRIMARY CANCERS IN THE IFCT-0302 TRIAL ASSESSING A CT-SCAN-BASED FOLLOW-UP AFTER LUNG CANCER SURGERY
• OA 04.06 SURGEON PRACTICES FOR POST RESECTION LUNG CANCER SURVEILLANCE: COMPARISONS OF STS AND ESTS MEMBERS

Discussion: Κ. Ηλιάδης (5 min)
Q & A

15:45- 16:15 SATELLITE LECTURE EDUCATIONAL SESSION
Chair: Α. Κωτσάκης, Λ. Τουφεξιάν
Presenter: Λ. Ζέλλος (25 min)
• ES 05.04 MINIMALLY INVASIVE SURGERY FOR LUNG CANCER, INCLUDING ROBOTICS

Q & A

16:15-17.05 DIAGNOSTIC RADIOLOGY, STAGING AND SCREENING FOR LUNG CANCER
Chairs: Γ. Τσοουκαλάς, Μ. Βασλαματζής
Presenter: Σ. Τσαγκούλη (20 min)
• PL 01.02 MAJOR ADVANCES IN CT SCREENING: A RADIOLOGIST'S PERSPECTIVE
• OA 15.01 LUNG CANCER SCREENING: PARTICIPANT SELECTION BY RISK MODEL – THE PAN–CANADIAN STUDY
• OA 15.02 BENEFITS, HARMS, AND ECONOMIC EFFICIENCY OF LOW-DOSE CT LUNG CANCER SCREENING STRATEGIES IN A POPULATION-BASED SETTING

Comment: Κ. Ταβερναράκη (10 min)
Q & A

Presenter: Σ. Τσιμπούκης (10 min)

• OA 15.03 GENE-BASED RISK STRATIFICATION OF NLST-ACRIN SCREENING PARTICIPANTS IDENTIFIES THE “SWEET SPOT” OF SCREENING (N=10,054)

• OA 15.08 THOROUGHNESS OF STAGING AND THE OUTCOMES OF SURGICAL RESSECTION OUTCOMES IN POTENTIALLY CURABLE NONSMALL CELL LUNG CANCER (NSCLC)

Comment: Μ. Βασλαματζής (5 min)
Q & A

17:05-17:30 Coffee break

17:30-18:30 TREATMENT ADVANCES IN SCLC
Chairs: Ν. Βαρδάκης, Α. Καραμπεάζης
Presenter 1: Κ. Ράπτη (15 min)

• OA 08.01 NEXT GENERATION SEQUENCING OF LARGE-CELL NEUROENDOCRINE CARCINOMA REVEALS AN ASSOCIATION OF PIK3CA MUTATIONS WITH BRAIN METASTASES

• OA 08.02 THE CORRELATION OF DLL3 EXPRESSION WITH HIGH-GRADE PULMONARY NEUROENDOCRINE CARCINOMA CLINICOPATHOLOGIC FEATURES AND PROGNOSSES

• OA 08.05 MAJOR DRIVERS OF CHEMOTHERAPY AND RADIATION UTILIZATION FOR LIMITED-STAGE SMALL CELL LUNG CANCER IN THE UNITED STATES

Presenter 2: Ν. Δεσσές (15 min)

• OA 08.06 EXPLORATORY ANALYSIS FOR PREDICTORS OF BENEFIT OF PARP INHIBITOR THERAPY IN EXTENSIVE STAGE SMALL CELL LUNG CANCER: ECOG-ACRIN 2511 STUDY

• OA 08.07 PAZOPANIB MAINTENANCE FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER: A RANDOMIZED, PLACEBOCONTROLLED PHASE II STUDY (KCSG-LU12-07)

Discussion: Ε. Κοντοπόδης (15 min)
Q & A

18:30- 19.45 EGFR TARGETED THERAPIES
Chairs: Γ. Κουμάκης, Ν. Κεντεποζίδης
Presenter 1: Τ. Μπηλίδας (15 min)

• OA 05.01 FIRST-LINE DACOMITINIB VERSUS Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

• OA 05.02 OSIMERTINIB VS SOC EGFR-TKI AS FIRST-LINE TREATMENT IN PATIENTS WITH EGFR-MUTATED NSCLC (FLAURA): PLASMA ctDNA ANALYSIS

• OA 07.05 SERIAL BIOPSIES IN PATIENTS WITH EGFR-MUTANT NSCLC HIGHLIGHT THE SPATIAL AND TEMPORAL HETEROGENEITY OF RESISTANCE MECHANISMS
• MA 12.05 GENOMIC PROFILING OF EGFR T790M MUTATED NONSMALL CELL LUNG CANCER TO EVALUATE THE MECHANISMS OF RESISTANCE TO OSIMERTINIB

Presenter 2: Ι. Κωτσαντής (15 min)

• OA 09.01 CHARACTERIZING THE GENOMIC LANDSCAPE OF EGFR C797S IN LUNG CANCER USING CIDNA NEXT-GENERATION SEQUENCING
• OA 09.02 OSIMERTINIB RESISTANCE MEDIATED BY LOSS OF EGFR T790M IS ASSOCIATED WITH EARLY RESISTANCE AND COMPETING RESISTANCE MECHANISMS
• OA 09.05 IDENTIFICATION OF NOVEL POTENTIALLY TARGETABLE GENOMIC ALTERATIONS IN PAIRED TUMORS WITH ACQUIRED EGFR TKI RESISTANCE BY NGS
• MA 12.11 THE ALTERATION OF T790M PREVALENCE BETWEEN 19 DELETIONS AND L858R IN NSCLC AFTER EGFR-TKIS THERAPY, A META-ANALYSIS

Presenter 3: Π. Κατσαούνης (15 min)

• OA 09.03 TATTON PH IB EXPANSION COHORT: OSIMERTINIB PLUS SAVOLITINIB FOR PTS WITH EGFR-MUTANT MET-AMPLIFIED NSCLC AFTER PROGRESSION ON PRIOR EGFR-TKI
• OA 09.07 CLONALITY OF C-MET COPY NUMBER GAIN AS A DETERMINANT OF PRIMARY TKI RESISTANCE IN EGFR-MUTANT NSCLC
• OA 16.04 EFFICACY AND SAFETY OF ERLOTINIB VS VINORELBINE/ CISPLATIN AS ADJUVANT THERAPY FOR STAGE IIIA EGFR MUTANT NSCLC PATIENTS
• MA 12.02 PHASE I/II STUDY OF S49076, A MET/AXL/FGFR INHIBITOR, COMBINED WITH GEFITINIB IN NSCLC PATIENTS PROGRESSING ON EGFR TKI

Discussion: Α. Αργύρης (15 min)

Q & A

19.45- 20:30 EDUCATIONAL SESSION
Chairs: Χ. Κουρούσης, Α. Κωτσάκης
Presenter: Ν. Κεντεποζίδης

ES 04.02 RESISTANCE MECHANISMS IN TKI

Q & A
FEBRUARY 24th 2018

09:00-11:00 PROGNOSTIC & PREDICTIVE BIOMARKERS

Chairs: Κ. Συρίγος, I. Μούντζιος
Presenter 1: Κ. Τσαπακίδης (20 min)

- OA 07.02 CHARACTERISTICS OF LUNG CANCER CELL-FREE TUMOR DNA (CFDNA) SHEDDING AND CORRELATION WITH TUMOR BURDEN AS MEASURED BY RECIST
- OA 07.03 CIRCULATING TUMOR DNA MUTANT ALLELE FREQUENCY AND TUMOR BURDEN AS BIOMARKERS FOR RESPONSE TO IMMUNE CHECKPOINT BLOCKADE
- OA 07.06 INNATE GENETIC EVOLUTION OF LUNG CANCERS AND SPATIAL HETEROGENEITY: ANALYSIS OF TREATMENT-NAÏVE LESIONS
- OA 07.08 CLINICAL POTENTIAL OF SPUTUM IN DETECTING DRIVER MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A PRELIMINARY STUDY

Discussion: Γ. Καλλέργη (15 min)
Q & A

Presenter 2: Α. Ζώη (20 min)

- OA 10.01 DETECTION OF EGFR MUTATIONS FROM PLASMA CTDNA IN THE OSIMERTINIB PHASE III TRIAL (AURA3): COMPARISON OF THREE PLASMA ASSAYS
- OA 10.02 UNIQUE GENETIC PROFILES FROM CIRCULATING CELLFREE DNA OF CEREBROSPINAL FLUID IN LEPTOMENINGEAL METASTASES OF EGFR MUTANT NSCLC
- OA 10.03 LIQUID BIOPSY IN THE LUNG CANCER CLINIC: A PROSPECTIVE STUDY OF PLASMA DNA NEXT GENERATION SEQUENCING TO GUIDE MATCHED THERAPY
- OA 10.06 LONGITUDINAL MUTATION MONITORING IN PLASMA BY DEEP SEQUENCING AS A POTENTIAL PREDICTOR OF DISEASE PROGRESSION IN NSCLC

Discussion: Φ. Παπαγεωργίου (15 min)
Q & A

Presenter 3: Μ. Παρασκευά (10 min)

- OA 10.07 GENOMIC PROFILE OF CELL-FREE DNA FROM SPUTUM, PLASMA, URINE AND TUMOR TISSUE AND CORRELATION WITH CLINICAL EFFECT IN ADVANCED NSCLC
- OA 18.04 WHOLE GENOME TUMOR-NORMAL SEQUENCING REVEALS POTENTIAL FALSE POSITIVES VERSUS STANDARD CGP SEQUENCING IN PATIENTS WITH NSCLC

Discussion: Α. Βουτσινά (15 min)
Q & A

Presenter 4: Μ. Ροβίθη (10 min)

- MA 01.03 THE POTENTIAL OF CNDA SEQUENCING IN DISEASE MONITORING AND DEPICTING GENOMIC EVOLUTION OF SMALL-CELL LUNG CANCER UNDER THERAPY
- MA 11.01 LIQUID BIOPSIES FOR MONITORING BRAF MUTATION (V600E) IN ADVANCED BRAF (V600E) NON-SMALL CELL LUNG CANCER (NSCLC)
- MA 07.13 NGS SEQUENCING BASED LIQUID / TISSUE BIOPSY IDENTIFIED COEXISTENCE OF HER2 AMPLIFICATION AND MUTATION IN ADVANCED NSCLC PATIENTS

Discussion: A. Βουτσινά (15 min)
Q & A
11:00-11:15 Coffee break

11:15-12:15 THE NEW ASPECT OF RADIATION THERAPY
Chairs: Ε. Μαραγκουδάκης, Ι. Βρούβας
Presenter 1: Α. Στεργιούλα (15 min)
• OA 01.02 STEREOTACTIC RADIOTHERAPY AS SALVAGE TREATMENT AFTER SURGERY AND CURATIVE INTENDED RADIOTHERAPY FOR PATIENTS WITH NSCLC
• OA 01.05 ANALYSIS OF RADIOTHERAPY QUALITY ASSURANCE DATA FOR THE CONVERT TRIAL - DOES NON-COMPLIANCE TO PROTOCOL AFFECT SURVIVAL?
• OA 01.06 RADIATION THERAPY IS ASSOCIATED WITH AN INCREASED INCIDENCE OF CARDIAC EVENTS IN SMALL CELL LUNG CANCER PATIENTS

Presenter 2: Γ. Φιλίππου (15 min)
• OA 01.07 TRACKING MAJOR SYMPTOM BURDEN FROM CHEMOTHERAPY CONCURRENT WITH 3D VS. IMRT VS. PROTON BEAM RADIOTHERAPY FOR NSCLC
• OA 16.01 STEREOTACTIC ABLATIVE RADIOTHERAPY VERSUS SURGERY IN EARLY LUNG CANCER: A META-ANALYSIS OF PROPENSITY SCORE-ADJUSTED STUDIES
• MA 09.01 A PROPENSITY-MATCHED ANALYSIS OF LOBECTOMY AND STEREOTACTIC BODY RADIOTHERAPY FOR EARLY STAGE NONSMALL CELL LUNG CANCER
• MA 09.06 PULMONARY OLIGOMETASTASES TREATED BY STEREOTACTIC BODY RADIATION THERAPY (SBRT): A NATIONWIDE SURVEY OF 1,378 PATIENTS

Discussion: Ε. Μπερούκας (15 min)
Q & A

12:15-13:15 ALK, HER-2 AND ROS REARRANGED ADVANCED/METASTATIC NSCLC
Chairs: Χ. Παπαδημητρίου, Λ. Βαμβακάς
Presenter 1: Γ. Ιωαννίδης (15 min)
• OA 05.05 BRIGATINIB IN CRIZOTINIB-REFRACTORY ALK+ NSCLC: UPDATED EFFICACY AND SAFETY RESULTS FROM ALTA, A RANDOMIZED PHASE 2 TRIAL
• OA 05.06 PHASE 2 STUDY OF LORLATINIB IN PATIENTS WITH ADVANCED ALK+ /ROS1+ NON-SMALL-CELL LUNG CANCER
• MA 07.08 CLINICAL IMPLICATIONS OF ALK RESISTANCE MUTATIONS: INSTITUTIONAL EXPERIENCE AND LAUNCH OF REMOTE PARTICIPATION STUDY
• MA 07.09 ALK/ROS1/TRK INHIBITOR TPX-0005 EFFECTIVELY OVERCOMES CLINICAL RESISTANCE SOLVENT FRONT MUTATIONS

Presenter 2: Ε. Λιανός (15 min)
• OA 05.07 EFFICACY AND UPDATED SAFETY OF CERITINIB (450 MG OR 600 MG) WITH LOW-FAT MEAL VS 750 MG FASTED IN ALK+ METASTATIC NSCLC
• OA 05.08 FINAL RESULT OF PHASE I/II STUDY (AF-001JP) OF ALECTINIB, A SELECTIVE CNS-ACTIVE ALK INHIBITOR, IN ALK+ NSCLC PATIENTS (PTS)
• MA 07.01 PATIENTS WITH ALK IHC-POSITIVE/FISH-NEGATIVE NSCLC BENEFIT FROM ALK TKI TREATMENT: RESPONSE DATA FROM THE GLOBAL ALEX TRIAL
Presenter 3: Δ. Νάση

- MA 07.11 A PHASE II STUDY OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE NON-SMALL-CELL-LUNG CANCER
- MA 07.12 SHORT-TERM CULTURE OF PATIENT DERIVED TUMOR ORGANOIDs IDENTIFY NERATINIB/TRASTUZUMAB AS AN EFFECTIVE COMBINATION IN HER2 MUTANT LUNG CANCER

Discussion: Μ. Μπακογεώργος (15 min)

Q & A

13:15-14:00 EMERGING GENOMIC TARGETS
Chairs: Ι. Δροσίτης, Γ. Ιωαννίδης
Presenter: Β. Ραμφίδης (25 min)

- OA 12.01 THE PRECLINICAL AND CLINICAL ACTIVITY OF POZIOTINIB, A POTENT, SELECTIVE INHIBITOR OF EGFR EXON 20 MUTANT NSCLC
- OA 12.02 FINAL RESULTS OF A PHASE 2 STUDY OF THE HSP90 INHIBITOR LUMINESPIB (AUY922) IN NSCLC PATIENTS HARBORING EGFR EXON 20 INSERTIONS
- OA 12.05 SPECTRUM OF 1,014 SOMATIC BRAF ALTERATIONS DETECTED IN CELL-FREE DNA OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
- OA 12.06 PLASMA GENOMIC PROFILING AND OUTCOMES OF PATIENTS WITH MET EXON 14-ALTERED NSCLCS TREATED WITH CRIZOTINIB ON PROFILE 1001
- OA 12.08 GENOMIC ANALYSIS OF NON-SMALL CELL LUNG CANCER (NSCLC) CASES WITH FOCAL AND NON-FOCAL MET AMPLIFICATION

Discussion: Β. Ραμφίδης (10 min)

Q & A

14:00-15:00 Light Lunch

15:00-15:55 NOVEL TARGETS AND BIOMARKERS IN MALIGNANT PLEURAL MESOTHELIOMA AND THYMOMAS
Chairs: Ε. Σαμαντάς, Ε. Κοντοπόδης
Presenter 1: J. Duran-Moreno (15 min)

- OA 02.02 IPILIMUMAB AND NIVOLUMAB IN THE TREATMENT OF RECURRENT MALIGNANT PLEURAL MESOTHELIOMA: A PHASE II STUDY
- MA 19.01 A PHASE II STUDY OF NIVOLUMAB: A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY IN MALIGNANT PLEURAL MESOTHELIOMA (MERIT)
- MA 19.02 TREMELIMUMAB PLUS DURVALUMAB IN FIRST- OR SECOND-LINE MESOTHELIOMA PATIENTS: FINAL ANALYSIS OF THE NIBIT-MESO-1 STUDY
- MA 19.03 NINTEDANIB + PEMETREXED/CISPLATIN IN MALIGNANT PLEURAL MESOTHELIOMA (MPM): PHASE II BIOMARKER DATA FROM THE LUMEMESO STUDY

Presenter 2: Κ. Σαιγαρίδας (15 min)

- OA 02.03 PROPHYLACTIC IRRADIATION OF TRACTS (PIT) IN PATIENTS WITH PLEURAL MESOTHELIOMA: RESULTS OF A MULTICENTRE PHASE III TRIAL
• OA 02.06 RADIOIMMUNOTHERAPY COMBINING CTLA-4 BLOCKADE OR LOW-DOSE CYCLOPHOSPHAMIDE WITH LOCAL RADIATION IN MURINE MALIGNANT MESOTHELIOMA

• OA 03.04 A PHASE II STUDY OF PEMBROLIZUMAB FOR PATIENTS WITH REFRACTORY OR RELAPSED THYMIC EPITHELIAL TUMOR

• MA 16.02 DIFFERENT PATTERN AND PROGNOSTIC ROLE OF PD-L1, IDO, AND FOXP3 TREG EXPRESSION IN THYMOMA AND THYMIC CARCINOMA

Discussion: Π. Κατσαούνης (15 min)
Q & A

15:55-16:50 IMMUNO-BIOLOGY
Chairs: Π. Κορκολοπούλου, Ε. Πατσέα
Presenter: L. Abou-Assabeh (30 min)

• PL 03.03 BLUEPRINT 2: PD-L1 IMMUNOHISTOCHEMISTRY COMPARABILITY STUDY IN REAL-LIFE, CLINICAL SAMPLES

• OA 13.02 DISTRIBUTION OF PD-L1 TUMOR EXPRESSION BY ASSAY TYPE IN PATIENTS WITH METASTATIC NSCLC (MNSCLC)

• OA 13.05 IMMUNE, MOLECULAR AND T CELL REPERTOIRE LANDSCAPE OF 235 RESECTED NON-SMALL CELL LUNG CANCERS AND PAIRED NORMAL LUNG TISSUES

• OA 13.06 CO-EXPRESSION OF IDO1 AND PD-L1 INDICATES MORE AGGRESSIVE FEATURES OF LUNG ADENOCARCINOMA

• OA 13.07 CONTRACTION OF T CELL CLONALITY IN LUNG CANCER METASTASES

Discussion: Α. Κουτσόπουλος (15 min)
Q & A

16:00-17:15 Coffee break

17:15-18:15 IMMUNOTHERAPY CHECKPOINT INHIBITORS IN ADVANCED NSCLC (I)
Chairs: Β. Γεωργούλιας, M. Τσιατάς
Presenter 1: N. Τσουκαλάς (20 min)

• PL 03.04 CURRENT STATUS AND FUTURE OF IMMUNOTHERAPY IN LUNG CANCER

• PL 02.02 PATIENT-REPORTED OUTCOMES WITH DURVALUMAB AFTER CHEMORADIATION IN LOCALLY ADVANCED, UNRESECTABLE NSCLC: DATA FROM PACIFIC

• MA 02.07 A PHASE II STUDY OF PEMBROLIZUMAB IN EGFR MUTANT, PD-L1+, TYROSINE KINASE INHIBITOR (TKI) NAÏVE PATIENTS WITH ADVANCED NSCLC

• MA 10.07 ELDERLY LUNG CANCER PATIENTS ON IMMUNOTHERAPY: PRELIMINARY RESULTS FROM THE ELDERS STUDY

Presenter 2: E. Ελευθεράκης (20 min)

• OA 17.02 UPDATED EFFICACY RESULTS FROM THE BIRCH STUDY: FIRST-LINE ATEZOLIZUMAB THERAPY IN PD-L1–SELECTED PATIENTS WITH ADVANCED NSCLC

• OA 17.05 IFCT-1502 CLINIVO: REAL-LIFE EXPERIENCE WITH NIVOLUMAB IN 600 PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER NSCLC

Discussion: Π. Κατσαούνης (15 min)
Q & A
• OA 17.06 UPDATED ANALYSIS OF KEYNOTE-024: PEMBROLIZUMAB VS PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NSCLC WITH PD-L1 TPS ≥50%

• OA 17.08 PHASE II STUDY OF PEMBROLIZUMAB FOR OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETION OF LOCALLY ABLATIVE THERAPY (LAT)

Discussion: Π. Οικονομόπουλος (15 min)

Q & A

18:15-19:10 IMMUNOTHERAPY CHECKPOINT INHIBITORS IN ADVANCED NSCLC (II)

Chairs: Κ.Ν. Μπαξεβάνης, Α. Κωτσάκης

Presenter 1: Ε. Κοντοπόδης (15 min)

• OA 17.01 PEMETREXED-CARBOPLATIN PLUS PEMBROLIZUMAB AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NSCLC: KEYNOTE-021 COHORT G UPDATE

• OA 17.03 FIRST-LINE NIVOLUMAB PLUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR ADVANCED NSCLC: CHECKMATE 012 3-YEAR UPDATE

• MA 02.05 NIVOLUMAB IN ADVANCED NON-SQUAMOUS NSCLC PATIENTS WITH KRAS MUTATIONS: RESULTS FROM THE ITALIAN EXPANDED ACCESS PROGRAM (EAP)

• MA 10.06 REAL-WORLD RESULTS IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS: ITALIAN NIVOLUMAB EXPANDED ACCESS PROGRAMME

Presenter 2: Β. Παπαδόπουλος (15 min)

• MA 03.09 THE COST AND THE BENEFIT: FRONT-LINE IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCER

• MA 10.01 DURVALUMAB ± TREMELIMUMAB WITH PLATINUM DOUBLETS IN NON-SMALL CELL LUNG CANCER: CANADIAN CANCER TRIALS GROUP STUDY IND.226

• MA 10.02 NAB-PACLITAXEL + DURVALUMAB AS SECOND- OR THIRD-LINE TREATMENT OF ADVANCED NSCLC: RESULTS FROM ABOUND.2L+

• MA 10.11 HYPERPROGRESSIVE DISEASE (HPD) IS FREQUENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) TREATED WITH ANTI PD1/PD-L1 AGENTS (IO)

• MA 02.02 PHASE 2 STUDY OF PEMBROLIZUMAB PLUS CC-486 VS PEMBROLIZUMAB PLUS PLACEBO IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NSCLC

Discussion: Ν. Πισταμαλτζίδας (15 min)

Q & A

19:10-19:30 Closing Remarks